Status and phase
Conditions
Treatments
About
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. Thereafter, sunitinib is initiated 50 mg/day; regimen 4/6 (Marketing Authorisation Indication), 4 weeks "on " alternating with 2 weeks "off "
As soon as a dose or schedule adjustment is required, regardless of cause, the patient will be randomised 1/1:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Men or women over 18 years old
Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication
Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component
Karnofsky performance status ≥ 70%
Adequate organ function:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
226 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal